Svenska English

CrossPharma logoprodlekpol-logo

Cross Pharma is active in the parallel import industry, importing original pharmaceuticals to Sweden. We are one of the larger companies active in this sector in the Swedish market and, when we started in the mid-1990s, were first company to parallel import original pharmaceuticals to this country. Today, we market approximately 250 products.
Since July 2013, Cross Pharma is owned by Unimedic Group.

We have 10 employees working at our head office in Stockholm, and approximately 50 working at our subsidiary Prodlekpol in Warsaw with pharmaceutical re-packaging.
Cross Pharma is approved and regularly inspected by the Swedish Medical Products Agency. We parallel import original pharmaceuticals from other EU countries only. We collaborate with about 70 suppliers in 20 European countries.
Pharmaceuticals are repackaged at our own repackaging centre outside Warsaw in Poland.

Since we have full control of the repackaging process, we can guarantee speedy product flow and maintain optimal stock levels. All products are provided with information customized for the Swedish market before they are sold on to the different pharmacy chains. Our products are covered by the Swedish Pharmaceutical Insurance Scheme.
Our operations help to create a competitive market and to maintain a downward pressure on the prices for prescription medicines protected by a patent. This is positive for pharmacies, since it means that the purchase prices for pharmaceuticals can be kept at a minimum, and positive for society as a whole, since it leads to an overall downward pressure on prices.

Cross Pharma is a member of the Swedish Association of Pharma Traders (Läkemedelshandlarna), the Swedish branch organization for the parallel import of pharmaceuticals. The Swedish Association of Pharma Traders is, in turn, a member of the European association of Euro-Pharmaceutical Companies, EAEPC.

What is parallel import?

Parallel import is based on the principle of free movement of goods and services within the EU, as laid out in the Treaty of Rome. The prices of pharmaceuticals vary considerably between member states and by taking advantage of these differences it is possible to create an opening for parallel trade.

The objective of parallel trade is to import approved prescription medicines to Sweden from other EU states, where they can be obtained at a lower price. A company active in the parallel import industry does not manufacture pharmaceuticals but imports pharmaceuticals which already exist on the European market. In other words, it is the same medicine, with the same active substance as on the Swedish market  that is bought, but it is repackaged and provided with Swedish text and patient information. Before Cross Pharma can sell pharmaceuticals that have entered Sweden through parallel import, the products must be approved by the Medical Products Agency or its European equivalent, EMA.

The bulk of parallel import involves pharmaceuticals still protected by a patent. Parallel import creates advantages for pharmacies on the new, regulated market, which also benefit consumers. The savings they have gained through parallel import have made improved accessibility, longer opening hours and better service possible.